First human study of LP-001 checks safety before MDS fight
NCT ID NCT06294275
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested the safety and tolerability of a new drug called LP-001 in 68 healthy adults aged 18 to 50. The goal was to see how the body handles single and multiple doses, not to treat any disease. Results will help guide future research for myelodysplastic syndrome (MDS), a blood disorder.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME (MDS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Public Health Clinical Center
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pill targets genetic weakness in Hard-to-Treat blood cancers
- New transplant cocktail aims to tame blood cancer without severe side effects
- Experimental drug tested for Post-Transplant blood cancers — but study halted early
- New drug cocktail shows promise for rare blood cancer
- New combo aims to cut infections in bone marrow cancer
- One donor, two transplants: could this end lifelong Anti-Rejection drugs?